The Discounted Cash Flow (DCF) valuation of Supernus Pharmaceuticals Inc (SUPN) is 39.83 USD. With the latest stock price at 52.02 USD, the upside of Supernus Pharmaceuticals Inc based on DCF is -23.4%.
Based on the latest price of 52.02 USD and our DCF valuation, Supernus Pharmaceuticals Inc (SUPN) is a sell. selling SUPN stocks now will result in a potential gain of 23.4%.
| Range | Selected | |
| WACC / Discount Rate | 5.6% - 7.3% | 6.5% |
| Long-term Growth Rate | 2.5% - 4.5% | 3.5% |
| Fair Price | 26.26 - 97.72 | 39.83 |
| Upside | -49.5% - 87.9% | -23.4% |